Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents

Htut K. Win, Angel E. Caldera, Kelly Maresh, John Lopez, Charanjit S. Rihal, Manish A. Parikh, Juan F. Granada, Sachin Marulkar, Deborah Nassif, David J. Cohen, Neal S. Kleiman

Research output: Contribution to journalArticle

308 Citations (Scopus)

Abstract

Context: Clinical trials that have excluded patients at high risk for cardiac events have led to commercial labeling approval of drug-eluting stents; nevertheless, such highrisk patients commonly undergo stent placement in clinical practice. The degree to which they experience cardiac events at a higher rate than non-high-risk patients is unclear. Objective: To assess the rates of major adverse cardiac events during the index admission and 1 year after the implantation of drug-eluting stents in patients with high-risk angiographic and clinical features. Design, Setting, and Patients: From July 2004 to September 2005, consecutive patients who underwent attempted stent placement at 42 different hospitals throughout the United States were enrolled in a prospective multicenter registry. We analyzed outcomes of 3323 patients who received at least 1 drug-eluting stent for a reason other than acute ST-segment elevation myocardial infarction. The study population was divided into 2 groups based on presence of at least 1 of 9 off-label characteristics based on the current US Food and Drug Administration-approved indications for sirolimus- and paclitaxel-eluting stents. Main Outcome Measures: The composite clinical outcomes of death, myocardial infarction, or target vessel revascularization during the index admission and death, myocardial infarction, or target lesion revascularization at 1 year were evaluated. Results: Of the 3323 patients, 1817 (54.7%) had at least 1 off-label characteristic. During the index hospitalization, the composite clinical outcome occurred in 198 (10.9%) of patients in the off-label group and 76 (5.0%) of patients in the on-label group (adjusted odds ratio, 2.32; 95% confidence interval [CI], 1.75-3.07; P<.001). At 1 year, the composite clinical outcome occurred more often in the off-label group compared with the on-label group; 309 (17.5%) vs 131 (8.9%) (adjusted hazard ratio [HR], 2.16; 95% CI, 1.74-2.67; P<.001). Stent thrombosis also occurred more frequently among patients in the off-label group during the initial hospitalization (8 [0.4%] vs 0) and at 1 year: 29 (1.6%) vs 13 (0.9%), adjusted HR, 2.29 (95% CI, 1.02-5.16; P=.05). Conclusions: Compared with on-label use, off-label use of drug-eluting stents is associated with a higher rate of adverse outcomes during the index admission and at 1 year. Stent thrombosis occurred predominantly in patients who underwent off-label drug-eluting stent implantation. Clinicians should be cautious about extrapolating the benefits of drug-eluting stents over bare-metal stents observed in randomized clinical trials to higher-risk clinical settings that have not been assessed.

Original languageEnglish (US)
Pages (from-to)2001-2009
Number of pages9
JournalJournal of the American Medical Association
Volume297
Issue number18
DOIs
StatePublished - May 9 2007

Fingerprint

Off-Label Use
Drug-Eluting Stents
Stents
Thrombosis
Confidence Intervals
Hospitalization
Myocardial Infarction
Sirolimus
United States Food and Drug Administration
Paclitaxel
Registries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Win, H. K., Caldera, A. E., Maresh, K., Lopez, J., Rihal, C. S., Parikh, M. A., ... Kleiman, N. S. (2007). Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. Journal of the American Medical Association, 297(18), 2001-2009. https://doi.org/10.1001/jama.297.18.2001

Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. / Win, Htut K.; Caldera, Angel E.; Maresh, Kelly; Lopez, John; Rihal, Charanjit S.; Parikh, Manish A.; Granada, Juan F.; Marulkar, Sachin; Nassif, Deborah; Cohen, David J.; Kleiman, Neal S.

In: Journal of the American Medical Association, Vol. 297, No. 18, 09.05.2007, p. 2001-2009.

Research output: Contribution to journalArticle

Win, HK, Caldera, AE, Maresh, K, Lopez, J, Rihal, CS, Parikh, MA, Granada, JF, Marulkar, S, Nassif, D, Cohen, DJ & Kleiman, NS 2007, 'Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents', Journal of the American Medical Association, vol. 297, no. 18, pp. 2001-2009. https://doi.org/10.1001/jama.297.18.2001
Win, Htut K. ; Caldera, Angel E. ; Maresh, Kelly ; Lopez, John ; Rihal, Charanjit S. ; Parikh, Manish A. ; Granada, Juan F. ; Marulkar, Sachin ; Nassif, Deborah ; Cohen, David J. ; Kleiman, Neal S. / Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. In: Journal of the American Medical Association. 2007 ; Vol. 297, No. 18. pp. 2001-2009.
@article{89de8b61923f44708c0343e8f81ef84b,
title = "Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents",
abstract = "Context: Clinical trials that have excluded patients at high risk for cardiac events have led to commercial labeling approval of drug-eluting stents; nevertheless, such highrisk patients commonly undergo stent placement in clinical practice. The degree to which they experience cardiac events at a higher rate than non-high-risk patients is unclear. Objective: To assess the rates of major adverse cardiac events during the index admission and 1 year after the implantation of drug-eluting stents in patients with high-risk angiographic and clinical features. Design, Setting, and Patients: From July 2004 to September 2005, consecutive patients who underwent attempted stent placement at 42 different hospitals throughout the United States were enrolled in a prospective multicenter registry. We analyzed outcomes of 3323 patients who received at least 1 drug-eluting stent for a reason other than acute ST-segment elevation myocardial infarction. The study population was divided into 2 groups based on presence of at least 1 of 9 off-label characteristics based on the current US Food and Drug Administration-approved indications for sirolimus- and paclitaxel-eluting stents. Main Outcome Measures: The composite clinical outcomes of death, myocardial infarction, or target vessel revascularization during the index admission and death, myocardial infarction, or target lesion revascularization at 1 year were evaluated. Results: Of the 3323 patients, 1817 (54.7{\%}) had at least 1 off-label characteristic. During the index hospitalization, the composite clinical outcome occurred in 198 (10.9{\%}) of patients in the off-label group and 76 (5.0{\%}) of patients in the on-label group (adjusted odds ratio, 2.32; 95{\%} confidence interval [CI], 1.75-3.07; P<.001). At 1 year, the composite clinical outcome occurred more often in the off-label group compared with the on-label group; 309 (17.5{\%}) vs 131 (8.9{\%}) (adjusted hazard ratio [HR], 2.16; 95{\%} CI, 1.74-2.67; P<.001). Stent thrombosis also occurred more frequently among patients in the off-label group during the initial hospitalization (8 [0.4{\%}] vs 0) and at 1 year: 29 (1.6{\%}) vs 13 (0.9{\%}), adjusted HR, 2.29 (95{\%} CI, 1.02-5.16; P=.05). Conclusions: Compared with on-label use, off-label use of drug-eluting stents is associated with a higher rate of adverse outcomes during the index admission and at 1 year. Stent thrombosis occurred predominantly in patients who underwent off-label drug-eluting stent implantation. Clinicians should be cautious about extrapolating the benefits of drug-eluting stents over bare-metal stents observed in randomized clinical trials to higher-risk clinical settings that have not been assessed.",
author = "Win, {Htut K.} and Caldera, {Angel E.} and Kelly Maresh and John Lopez and Rihal, {Charanjit S.} and Parikh, {Manish A.} and Granada, {Juan F.} and Sachin Marulkar and Deborah Nassif and Cohen, {David J.} and Kleiman, {Neal S.}",
year = "2007",
month = "5",
day = "9",
doi = "10.1001/jama.297.18.2001",
language = "English (US)",
volume = "297",
pages = "2001--2009",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "18",

}

TY - JOUR

T1 - Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents

AU - Win, Htut K.

AU - Caldera, Angel E.

AU - Maresh, Kelly

AU - Lopez, John

AU - Rihal, Charanjit S.

AU - Parikh, Manish A.

AU - Granada, Juan F.

AU - Marulkar, Sachin

AU - Nassif, Deborah

AU - Cohen, David J.

AU - Kleiman, Neal S.

PY - 2007/5/9

Y1 - 2007/5/9

N2 - Context: Clinical trials that have excluded patients at high risk for cardiac events have led to commercial labeling approval of drug-eluting stents; nevertheless, such highrisk patients commonly undergo stent placement in clinical practice. The degree to which they experience cardiac events at a higher rate than non-high-risk patients is unclear. Objective: To assess the rates of major adverse cardiac events during the index admission and 1 year after the implantation of drug-eluting stents in patients with high-risk angiographic and clinical features. Design, Setting, and Patients: From July 2004 to September 2005, consecutive patients who underwent attempted stent placement at 42 different hospitals throughout the United States were enrolled in a prospective multicenter registry. We analyzed outcomes of 3323 patients who received at least 1 drug-eluting stent for a reason other than acute ST-segment elevation myocardial infarction. The study population was divided into 2 groups based on presence of at least 1 of 9 off-label characteristics based on the current US Food and Drug Administration-approved indications for sirolimus- and paclitaxel-eluting stents. Main Outcome Measures: The composite clinical outcomes of death, myocardial infarction, or target vessel revascularization during the index admission and death, myocardial infarction, or target lesion revascularization at 1 year were evaluated. Results: Of the 3323 patients, 1817 (54.7%) had at least 1 off-label characteristic. During the index hospitalization, the composite clinical outcome occurred in 198 (10.9%) of patients in the off-label group and 76 (5.0%) of patients in the on-label group (adjusted odds ratio, 2.32; 95% confidence interval [CI], 1.75-3.07; P<.001). At 1 year, the composite clinical outcome occurred more often in the off-label group compared with the on-label group; 309 (17.5%) vs 131 (8.9%) (adjusted hazard ratio [HR], 2.16; 95% CI, 1.74-2.67; P<.001). Stent thrombosis also occurred more frequently among patients in the off-label group during the initial hospitalization (8 [0.4%] vs 0) and at 1 year: 29 (1.6%) vs 13 (0.9%), adjusted HR, 2.29 (95% CI, 1.02-5.16; P=.05). Conclusions: Compared with on-label use, off-label use of drug-eluting stents is associated with a higher rate of adverse outcomes during the index admission and at 1 year. Stent thrombosis occurred predominantly in patients who underwent off-label drug-eluting stent implantation. Clinicians should be cautious about extrapolating the benefits of drug-eluting stents over bare-metal stents observed in randomized clinical trials to higher-risk clinical settings that have not been assessed.

AB - Context: Clinical trials that have excluded patients at high risk for cardiac events have led to commercial labeling approval of drug-eluting stents; nevertheless, such highrisk patients commonly undergo stent placement in clinical practice. The degree to which they experience cardiac events at a higher rate than non-high-risk patients is unclear. Objective: To assess the rates of major adverse cardiac events during the index admission and 1 year after the implantation of drug-eluting stents in patients with high-risk angiographic and clinical features. Design, Setting, and Patients: From July 2004 to September 2005, consecutive patients who underwent attempted stent placement at 42 different hospitals throughout the United States were enrolled in a prospective multicenter registry. We analyzed outcomes of 3323 patients who received at least 1 drug-eluting stent for a reason other than acute ST-segment elevation myocardial infarction. The study population was divided into 2 groups based on presence of at least 1 of 9 off-label characteristics based on the current US Food and Drug Administration-approved indications for sirolimus- and paclitaxel-eluting stents. Main Outcome Measures: The composite clinical outcomes of death, myocardial infarction, or target vessel revascularization during the index admission and death, myocardial infarction, or target lesion revascularization at 1 year were evaluated. Results: Of the 3323 patients, 1817 (54.7%) had at least 1 off-label characteristic. During the index hospitalization, the composite clinical outcome occurred in 198 (10.9%) of patients in the off-label group and 76 (5.0%) of patients in the on-label group (adjusted odds ratio, 2.32; 95% confidence interval [CI], 1.75-3.07; P<.001). At 1 year, the composite clinical outcome occurred more often in the off-label group compared with the on-label group; 309 (17.5%) vs 131 (8.9%) (adjusted hazard ratio [HR], 2.16; 95% CI, 1.74-2.67; P<.001). Stent thrombosis also occurred more frequently among patients in the off-label group during the initial hospitalization (8 [0.4%] vs 0) and at 1 year: 29 (1.6%) vs 13 (0.9%), adjusted HR, 2.29 (95% CI, 1.02-5.16; P=.05). Conclusions: Compared with on-label use, off-label use of drug-eluting stents is associated with a higher rate of adverse outcomes during the index admission and at 1 year. Stent thrombosis occurred predominantly in patients who underwent off-label drug-eluting stent implantation. Clinicians should be cautious about extrapolating the benefits of drug-eluting stents over bare-metal stents observed in randomized clinical trials to higher-risk clinical settings that have not been assessed.

UR - http://www.scopus.com/inward/record.url?scp=34248376428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248376428&partnerID=8YFLogxK

U2 - 10.1001/jama.297.18.2001

DO - 10.1001/jama.297.18.2001

M3 - Article

VL - 297

SP - 2001

EP - 2009

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 18

ER -